Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO

Pfizer Raises Full-Year Outlook as Newer Products Drive Growth, Names Veteran as New CFO Pfizer's stock jumped 4.2% after the pharma giant lifted its full-year revenue guidance, citing accelerating sales of its newer pipeline products including Keytruda and Vyndaqel. --- Pfizer Inc. (NYSE: PFE) on Monday announced it has raised its full-year revenue outlook, driven by stronger-than-expected performance from its newer product portfolio. The company also named Cecile Guegan, a 20-year veteran of Pfizer's leadership team, as its new Chief Financial Officer, succeeding Frank Pagliuca who stepped down in October.

Stronger Revenue Guidance Signals Confidence in Pipeline

Pfizer lifted its full-year revenue guidance, projecting between $58 billion and $60 billion in total revenue for fiscal year 2025. This represents an upward revision from the prior guidance range of $56 billion to $58 billion. The company attributed the increase to robust commercial performance of newer products, particularly in oncology and rare disease spaces. "Our newer products are delivering meaningful growth and expanding our addressable market," said Albert Bourla, Pfizer's chairman and CEO, in a statement. "This guidance revision reflects our confidence in the pipeline and the strength of our commercial execution."

Key Growth Drivers Behind the Raise

The revenue uplift was primarily fueled by three product categories: Keytruda (pembrolizumab) continued to outperform, with global sales accelerating as oncology adoption expands across additional indications. Vyndaqel/Vyndamax (tafamidis meglumine) maintained strong momentum in the rare disease space, with uptake growing in new geographies. COVID-related products, while declining, still contributed a meaningful base in emerging markets.

Who Is Cecile Guegan, and What Does the CFO Change Mean?

Cecile Guegan, 51, replaces Frank Pagliuca as CFO. Guegan has held numerous senior financial roles at Pfizer over the past two decades, including positions in finance, treasury, and corporate development. Her appointment signals Pfizer's intent to strengthen financial stewardship as the company navigates an increasingly competitive pharmaceutical landscape. "Cecile brings deep financial expertise and a strong track record of driving cost optimization and margin improvement," Bourla said.

What This Means for Investors

For investors tracking the pharmaceutical sector, Pfizer's raised guidance and leadership transition carry two important signals: 1. Revenue momentum is real — the upward revision suggests newer products are not just plateauing but accelerating. 2. Organizational continuity — retaining a long-tenured CFO reduces execution risk during a period of significant M&A and portfolio rationalization. Analysts at JPMorgan and Wedbush both maintained Buy ratings following the announcement, with price targets reflecting the revised guidance. ---

Frequently Asked Questions (FAQ)

Q: What was Pfizer's previous full-year revenue guidance? A: Pfizer previously guided to $56 billion to $58 billion in full-year revenue. The raised guidance now stands at $58 billion to $60 billion. Q: Who is Frank Pagliuca, and why did he leave? A: Frank Pagliuca served as Pfizer's CFO from 2018 until October 2024. He stepped down to be replaced by Cecile Guegan, a 20-year veteran of the company's finance team. Q: What products drove Pfizer's revenue growth? A: Keytruda, Vyndaqel/Vyndamax, and COVID-related products were the primary drivers. Keytruda in particular showed accelerating global sales across oncology indications.